All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions...
Data include the persistence of immune responses and protection against variants of concern, especially Delta and OmicronOcugen has North American...
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Patent Covers Jet Delivery of GLP-1 Receptor Agonists to the Small Intestine for Treatment of Any Disease Including Type 2...
HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Study has reached extended enrollment target of 160 patients Top-line data...
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
TriLink now offers GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate, a critical raw material for mRNA manufacturing, allowing researchers to accelerate their drug discovery and...
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the standard of care for seasonal...
JUPITER, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of...
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD...
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN...
Standardized methodology demonstrates high presence of placental membrane growth factors in BioStem’s Vendaje® and Vendaje AC®tissue allografts POMPANO BEACH, FLORIDA.,...
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, September 13, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage...
-The IND for AK-OTOF is the first to receive FDA clearance for a genetic form of hearing loss and the...
Award to fund clinical study of Marker’s multi-antigen targeted T cell therapy for the treatment of post-transplant AML patients with...
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as...